Mallinckrodt plc, a Dublin-based pharmaceutical company, has established a prominent international presence through the development, manufacturing, marketing, and distribution of specialty medication and therapies across the globe. The company's operations focus on two segments: Specialty Brands and Specialty Generics. Boasting an impressive array of branded pharmaceuticals, including treatments for neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology, Mallinckrodt plc is also active in the immunotherapy and neonatal respiratory critical care sectors. In addition, the company produces specialty generic drugs and active pharmaceutical ingredients. With a strong emphasis on physician and pharmacy engagement, Mallinckrodt plc markets its branded products to a broad customer base in hospitals, ambulatory surgical centers, and specialty pharmacies, among many others. Founded in 1867, Mallinckrodt plc continues to expand its global footprint as it develops Terlipressin for the treatment of hepatorenal syndrome.